Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused
on the development of central nervous system therapies based on its
neural stem cell technology, announced poster presentations at two
upcoming scientific conferences. Presentations include
preclinical data in both of the company’s stem cell and small
molecule platforms at the Society for Neurosciences Annual Meeting,
as well as the American College of Toxicology Annual Meeting.
Following is a schedule of relevant
presentations:
2016 American College of Toxicology
Annual Meeting
Title: “Comprehensive In Vivo Nonclinical
Safety Assessment of NSI-189, a Small Molecule New Chemical Entity
for the Treatment of Major Depressive
Disorder”Date: Monday, November 7
Time: 5:30-7 PM
ESTPresenter: Grace Furman, PhD, CEO Paracelsus,
IncLocation: Baltimore Marriott
Waterfront, Baltimore, MD
2016 Society for Neurosciences Annual
Meeting
Title: "NSI-189, a neurogenic compound
enhances short-term and long-term potentiation in C57BL/6 mice and
reverses LTP impairment in a mouse model of Angelman
Syndrome”Date: Sunday, November 13
Time: 1-5 PM
PTPresenter: Michel Baudry, PhD, Graduate College
of Biomedical Sciences, Western University of
Health Location: San Diego Convention Center
(San Diego, CA)
Title: “Durable engraftment, neuronal
differentiation of human fetal neural stem cell transplants in
penetrating ballistic-like brain injury accompanied by amelioration
of cognitive deficits.”Date: Monday,
November 14
Time: 8AM-12PM PTPresenter: Shyam
Gajavelli, PhD, University of Miami Location:
San Diego Convention Center (San Diego, CA)
Title: “Induction of immune tolerance by
short-course immunosuppression after spinal grafting of allogeneic
neural precursors in pigs with previous chronic spinal cord
traumatic injury”Date: Monday, November 14
Time: 8AM-12PM
PTPresenter: Martin Marsala, MD, University of San
Diego School of Medicine Location: San
Diego Convention Center (San Diego, CA)
Title: “Remyelinating human oligodendrocyte
progenitors for regenerative treatment of demyelinating diseases
and spinal cord injury”Date: Wed,
November 16 Time:
8AM-12PM PTPresenter: Tom Hazel, PhD, VP of
Research, Neuralstem, Inc. Location:
San Diego Convention Center (San Diego, CA)
About Neuralstem
Neuralstem's patented technology enables the
commercial-scale production of multiple types of central nervous
system stem cells, which are being developed as potential therapies
for multiple central nervous system diseases and conditions.
Neuralstem’s technology enables the generation
of small molecule compounds by screening hippocampal stem cell
lines with its proprietary systematic chemical screening
process. The screening process has led to the discovery and
patenting of molecules that Neuralstem believes may stimulate the
brain's capacity to generate new neurons, potentially reversing
pathophysiologies associated with certain central nervous system
(CNS) conditions.
The company has completed Phase 1a and 1b trials
evaluating NSI-189, a novel neurogenic small molecule product
candidate, for the treatment of major depressive disorder or MDD,
and is currently conducting a Phase 2 efficacy study for MDD.
Neuralstem's stem cell therapy product
candidate, NSI-566, is a spinal cord-derived neural stem cell line.
Neuralstem is currently evaluating NSI-566 in three indications:
stroke, chronic spinal cord injury (cSCI), and Amyotrophic Lateral
Sclerosis (ALS).
Neuralstem is conducting a Phase 1 safety study
for the treatment of paralysis from chronic motor stroke at the
BaYi Brain Hospital in Beijing, China. In addition, NSI-566
was evaluated in a Phase 1 safety study to treat paralysis due to
chronic spinal cord injury, as well as, a Phase 1 and Phase 2a risk
escalation, safety trials for ALS. Patients from all three
indications are currently in long-term observational follow-up
periods to continue to monitor safety and possible therapeutic
benefits.
Cautionary Statement Regarding Forward Looking Information:
This news release contains "forward-looking
statements" made pursuant to the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements relate to future, not past, events and
may often be identified by words such as "expect," "anticipate,"
"intend," "plan," "believe," "seek" or "will." Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain.
Specific risks and uncertainties that could
cause our actual results to differ materially from those expressed
in our forward-looking statements include risks inherent in the
development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential
factors that could affect our results and other risks and
uncertainties are detailed from time to time
in Neuralstem's periodic reports, including the Annual
Report on Form 10-K for the year ended December 31, 2015, and
filed with the Securities and Exchange Commission (SEC)
on March 14, 2016, Form 10-Q for the period ended June
30, 2016, and in other reports filed with the SEC.
Contact:
Neuralstem – Investor Relations:
Danielle Spangler
301.366.1481
Planet Communications - Media Relations:
Deanne Eagle
917.837.5866
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Sep 2023 to Sep 2024